Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity
Authors:
Open Access
- 29 November 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1021823
Abstract
The paralogous oncogenic transcriptional coactivators YAP and TAZ are the distal effectors of the Hippo signaling pathway, which plays a critical role in cell proliferation, survival and cell fate specification. They are frequently deregulated in most human cancers, where they contribute to multiple aspects of tumorigenesis including growth, metabolism, metastasis and chemo/immunotherapy resistance. Thus, they provide a critical point for therapeutic intervention. However, due to their intrinsically disordered structure, they are challenging to target directly. Since YAP/TAZ exerts oncogenic activity by associating with the TEAD1-4 transcription factors, to regulate target gene expression, YAP activity can be controlled indirectly by regulating TEAD1-4. Interestingly, TEADs undergo autopalmitoylation, which is essential for their stability and function, and small-molecule inhibitors that prevent this posttranslational modification can render them unstable. In this article we report discovery of a novel small molecule inhibitor of YAP activity. We combined structure-based virtual ligand screening with biochemical and cell biological studies and identified JM7, which inhibits YAP transcriptional reporter activity with an IC50 of 972 nMoles/Ltr. Further, it inhibits YAP target gene expression, without affecting YAP/TEAD localization. Mechanistically, JM7 inhibits TEAD palmitoylation and renders them unstable. Cellular thermal shift assay revealed that JM7 directly binds to TEAD1-4 in cells. Consistent with the inhibitory effect of JM7 on YAP activity, it significantly impairs proliferation, colony-formation and migration of mesothelioma (NCI-H226), breast (MDA-MB-231) and ovarian (OVCAR-8) cancer cells that exhibit increased YAP activity. Collectively, these results establish JM7 as a novel lead compound for development of more potent inhibitors of TEAD palmitoylation for treating cancer.Keywords
All Related Versions
This publication has 53 references indexed in Scilit:
- Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathwayNature Chemical Biology, 2016
- Targeting YAP-Dependent MDSC Infiltration Impairs Tumor ProgressionCancer Discovery, 2016
- Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway SignalingStructure, 2016
- MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathwayNature Communications, 2015
- Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoproteinOncogene, 2015
- Role of Merlin/NF2 inactivation in tumor biologyOncogene, 2015
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesNature Genetics, 2015
- The cellular thermal shift assay for evaluating drug target interactions in cellsNature Protocols, 2014
- Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2Cell, 2013
- Role of YAP/TAZ in mechanotransductionNature, 2011